Iovance Biotherapeutics reported strong commercial momentum for its melanoma therapy, Amtagvi, at the Wells Fargo 21st Annual Healthcare Conference.
Real-world evidence shows patient response rates exceeding 50% for the treatment. Manufacturing efficiencies helped gross margins climb to 56%.
Amtagvi sales reached a record $91 million in the second quarter. The company plans to update its full-year guidance later this quarter.
Iovance confirmed its cash runway now extends into the second half of 2028.